The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Coherus BioSciences Inc

Nasdaq: CHRS
Last

(U.S.) $13.30

Today's change-0.20 -1.48%
Updated September 26 2:15 PM -4GMT. Delayed by at least 15 minutes.
 

Coherus BioSciences Inc

Nasdaq: CHRS
Last

(U.S.) $13.30

Today's change-0.20 -1.48%
Updated September 26 2:15 PM -4GMT. Delayed by at least 15 minutes.

Coherus BioSciences Inc crosses below 20-day moving average

Coherus BioSciences Inc is lower today, dropping (U.S.)$0.20 or 1.48% to (U.S.)$13.30 and crossing below its 20-day moving average. Over the last five days, shares have gained 3.50%, but are down 52.75% for the last year to date. Shares have underperformed the S&P 500 by 71.67% during the last year.

Key company metrics

  • Open(U.S.) $13.55
  • Previous close(U.S.) $13.50
  • High(U.S.) $13.80
  • Low(U.S.) $13.20
  • Bid / Ask(U.S.) $13.25 / (U.S.) $13.35
  • YTD % change-52.75%
  • Volume245,563
  • Average volume (10-day)525,334
  • Average volume (1-month)534,060
  • Average volume (3-month)726,572
  • 52-week range(U.S.) $10.80 to (U.S.) $31.48
  • Beta--
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$2.70
Updated September 26 2:15 PM -4GMT. Delayed by at least 15 minutes.
S&P TSX0.32%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2017Q1/2017Q4/2016Q3/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016
Revenue101163
Total other revenue--------
Total revenue101163
Gross profit--------
Total cost of revenue--------
Total operating expense58737478
Selling / general / administrative24191514
Research & development35545965
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-57-72-7385
Interest income (expense), net non-operating-2-2-2-2
Gain (loss) on sale of assets--------
Other--------
Income before tax-55-75-7684
Income after tax-55-75-7684
Income tax, total--------
Net income-55-75-7684
Total adjustments to net income--------
Net income before extra. items-55-75-7684
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-55-75-7684
Inc. avail. to common incl. extra. items-55-75-7684
Diluted net income-55-75-7684
Dilution adjustment------0
Diluted weighted average shares51494452
Diluted EPS excluding extraordinary itemsvalue per share-1.08-1.54-1.711.63
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-1.07-1.54-1.711.63